genetic engineering
The firm is developing genetic reporters designed to be selectively expressed by cancer cells, producing markers detectable by imaging or other readouts.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
Sherlock Biosciences Closes $31M Series A Financing Round
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.